Phospholipids affect stratum corneum lipid bilayer fluidity and drug partitioning into the bilayers.
Phospholipids, e.g. fluid-state EPC (l-alpha-phosphatidylcholine from egg yolk), may diffuse into the stratum corneum and enhance dermal and transdermal drug penetration, while many other phospholipids, e.g. gel-state DSPC (distearoylphosphatidyl choline), are not able to do this. These effects are suggested to be due to the interactions between the phospholipids and the skin lipid bilayers, and so an in vitro method was developed to evaluate the influence of phospholipids on the distribution of drugs to stratum corneum lipids. The distribution coefficients of estradiol, progesterone and propranolol between stratum corneum lipid liposomes (SCLLs) without phospholipids or with EPC, DSPC, SPC (l-alpha-phosphatidylcholine from soybean) or DOPE (dioleylphosphatidyl ethanolamine), and pH 7.4 buffer were determined. Fluid-state phospholipids in SCLLs increased the partitioning of drugs into SCLLs, while gel-state lipid, DSPC, did not. The increased distribution of drugs into the SCLLs was at least partially due to the increased fluidity of SCLL bilayers by phospholipids, which was shown using steady-state fluorescence anisotropy. This in vitro method enables screening of the effects of phospholipids and other permeation enhancers on stratum corneum bilayer fluidity and drug partitioning.
Department of Pharmaceutics, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland. mhakkara@uku.fi
M
M
Kirjavainen
J
J
Mönkkönen
M
M
Saukkosaari
R
R
Valjakka-Koskela
J
J
Kiesvaara
A
A
Urtti
D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000493:pharmacokinetics; D016880:Anisotropy; D004337:Drug Carriers; D004958:Estradiol / Q000008:administration & dosage / Q000493:pharmacokinetics; D008051:Lipid Bilayers / Q000737:chemistry*; D008081:Liposomes; D008560:Membrane Fluidity / Q000187:drug effects*; D010713:Phosphatidylcholines / Q000494:pharmacology; D010743:Phospholipids / Q000494:pharmacology*; D011374:Progesterone / Q000008:administration & dosage / Q000493:pharmacokinetics; D011433:Propranolol / Q000008:administration & dosage / Q000493:pharmacokinetics; D012867:Skin / Q000737:chemistry* / Q000187:drug effects*
D000319:Adrenergic beta-Antagonists; D004337:Drug Carriers; D008051:Lipid Bilayers; D008081:Liposomes; D010713:Phosphatidylcholines; D010743:Phospholipids; D011374:Progesterone; D004958:Estradiol; D011433:Propranolol